Preclinical efficacy and safety studies of ADAM33 oligonucleotides as new disease-modifying asthma therapy | University of 天发娱乐棋牌_天发娱乐APP-官网|下载_天发娱乐棋牌_天发娱乐APP-官网|下载
Study of the asthma susceptibility gene A Disintegrin and Metalloprotease 33 (ADAM33) in early life and adult asthma and other chronic lung diseases.
Development of novel Anti-ADAM33 agents as potential disease modifying asthma therapy.
Multiomic study of the influence of the maternal environment (e.g. allergic asthma, obesity) during pregnancy on ADAM33 and other mediators and the early origin of lung disease in the Maternal Environment in Pregnancy (MEP) cohort.